Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hutchmed
Pharma
Eli Lilly partner Hutchmed scraps stomach cancer filing
Thanks to regulators' doubts around overall survival data, Hutchmed has decided to withdraw an application in second-line stomach cancer.
Angus Liu
Aug 30, 2024 10:39am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia
Nov 10, 2023 8:05am
FDA signs off on Takeda's colorectal cancer drug Fruzaqla
Nov 9, 2023 10:54am
Moderna, GSK and Glenmark—Fierce Pharma Asia
Aug 25, 2023 9:20am
Taiho wins FDA nod for stronger colorectal cancer regimen
Aug 2, 2023 4:17pm
